Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II FS-1502 monotherapy in HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2500101151Phase 2Completed
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- May 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of caxmotabart entudotin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (4 cohorts), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Objective response rate and Safety. Started May 2022; status: completed.
02
Drugs
caxmotabart entudotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500101151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101151.